120
Participants
Start Date
March 31, 2014
Primary Completion Date
January 31, 2021
Study Completion Date
October 31, 2023
Nintedanib
Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
Placebo
Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
UZ Leuven, Leuven
CHU de Liège, Liège
Hospital Provincial Reina Sofia, Córdoba
H. Ramón y Cajal, Madrid
Hospital Clinico San Carlos, Madrid
Hospital Universitario Morales Meseguer, Murcia
CHU Saint-Pierre, Brussels
Institut Jules Bordet, Brussels
Grand Hopital de Charleroi, Charleroi
UZ Antwerpen, Edegem
AZ Groeninge, Kortrijk
CHR Citadelle, Liège
Clinique et maternite St. Elisabeth, Namur
Cliniques Universitaires mont godinne, Yvoir
Charité Med Uni Berlin, Berlin
Universitätsklinikum Carl Gustav Carus Dresden, Dresden
Kliniken Essen Mitte, Essen
Georg-August University Göttingen, Göttingen
Medical University Greifswald, Greifswald
University Tübingen, Tübingen
Centro Riferimento Oncologico, Aviano
Spedali Civili, Brescia
Azienda Ospedaliera Cannizzaro, Catania
National Cancer Institute, Milan
Istituto Nazionale Tumori-Pascale Naples, Naples
Padova Istituti Oncologico Veneto, Padua
University Pisa, Pisa
AUSL Reggio Emilia, Reggio Emilia
Poloclinico A Gemelli, Rome
Mauriziano -Torino, Torino
S. Anna Torino, Torino
Hospital Son Llatzer, Palma Mallorca
Grupo Español de Investigación en Cáncer de Ovario
OTHER
Mario Negri Gynecologic Oncology group (MaNGO)
OTHER
Multicenter Italian Trials in Ovarian Cancer (MITO)
UNKNOWN
North Eastern German Society of Gynaecological Oncology
OTHER
Belgian Gynaecological Oncology Group
OTHER